To the full analysis
Autolus Therapeutics stock: growth
AUTLAutolus Therapeutics reported $75.56M in revenue for fiscal 2025, up 646.7% on the prior year, up 113.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
95.2%
per year from 2014 to 2025, per share 45.2%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2014 | |
|---|---|---|
| Revenue | 113.2% | 95.2% |
| Revenue per share | 53.5% | 45.2% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2014 | $94.11K | −$7.46M | −$4.09M |
| 2015 | $1.21M | −$12.55M | −$11.7M |
| 2016 | $1.69M | −$19.73M | −$19.24M |
| 2017 | $1.05M | −$31.11M | −$34.62M |
| 2019 | $2.91M | −$123.85M | −$120.15M |
| 2020 | $1.72M | −$142.09M | −$132.44M |
| 2021 | $1.51M | −$142.1M | −$126.72M |
| 2022 | $6.19M | −$148.84M | −$123.15M |
| 2023 | $1.7M | −$208.38M | −$156.57M |
| 2024 | $10.12M | −$220.66M | −$241.09M |
| 2025 | $75.56M | −$288.2M | −$310.7M |
Revenue by segment
How Autolus Therapeutics plc makes its money and how that has shifted. Names are as the company reports them.
- Product$74.3M98%
- License$1.1M1%
The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| Product | $74.32M | 98.4% |
| License | $1.07M | 1.4% |
| Total revenue | $75.56M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2019)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.